Perla Development is a training, facilitation and executive coaching consultancy, specialising in leadership, management and professional development, (primarily within the life sciences sector). Founded in 2014, and run by Liz Mercer, Perla Development offers executive coaching, leadership and management development programmes, workshop design and delivery, team development and meetings facilitation.
Perla’s flagship development programme is the Management Essentials Programme for first line leaders which has been running since 2022. Commencing in February 2026, (in partnership with Matt Evans of Fired-Up Talent), the Expert Leader Programme will also be running for middle to senior leaders in the life sciences.
Both these programmes are open programmes with participation from across the industry. Liz also works with many clients providing training and development in a variety of topics: coaching skills, feedback, delegation, difficult conversations, managing performance, leading change, motivation and engagement, to name but a few. Her recent clients include, OMass Therapeutics, Charm Therapeutics, Microbiotica Ltd, T-therapeutics, Alchemab, Vernalis, Besins Healthcare and Ensocell.
Liz utilises a number of industry-leading models and tools in her work such as the Myers Briggs Type Indicator (MBTI), Korn Ferry competencies, Hogan, 360 feedback tools and the Key Polarity Indicator.
Perla Development is offering a discount to One Nucleus members. For more information please see https://onenucleus.com/perla-development
To get in touch with Liz at Perla Development you can:
• message directly, or call 07825 229686
• email her at [email protected]
• or message via LinkedIn https://www.linkedin.com/in/lizmercer1/
Perla’s flagship development programme is the Management Essentials Programme for first line leaders which has been running since 2022. Commencing in February 2026, (in partnership with Matt Evans of Fired-Up Talent), the Expert Leader Programme will also be running for middle to senior leaders in the life sciences.
Both these programmes are open programmes with participation from across the industry. Liz also works with many clients providing training and development in a variety of topics: coaching skills, feedback, delegation, difficult conversations, managing performance, leading change, motivation and engagement, to name but a few. Her recent clients include, OMass Therapeutics, Charm Therapeutics, Microbiotica Ltd, T-therapeutics, Alchemab, Vernalis, Besins Healthcare and Ensocell.
Liz utilises a number of industry-leading models and tools in her work such as the Myers Briggs Type Indicator (MBTI), Korn Ferry competencies, Hogan, 360 feedback tools and the Key Polarity Indicator.
Perla Development is offering a discount to One Nucleus members. For more information please see https://onenucleus.com/perla-development
To get in touch with Liz at Perla Development you can:
• message directly, or call 07825 229686
• email her at [email protected]
• or message via LinkedIn https://www.linkedin.com/in/lizmercer1/
Regulatory Consultancy
PharmaMedic provides a comprehensive outsourced virtual medical and regulatory affairs service for start-ups, mid to late-stage biopharma, as well as consumer health organisations, medical device companies, and academic centres. We deliver our virtual medical and regulatory affairs solutions through a team of experienced pharmaceutical consultants. We provide a range of flexible services supporting start-ups, product launches, and large pharma teams.
For more information visit our website https://pharmamedic.co/
Download our capabilities brochure here https://pharmamedic.co/wp-content/uploads/2020/09/PMC-Capabilities.pdf
Watch our Member Showcase Video https://bit.ly/3rzlfvd
For more information visit our website https://pharmamedic.co/
Download our capabilities brochure here https://pharmamedic.co/wp-content/uploads/2020/09/PMC-Capabilities.pdf
Watch our Member Showcase Video https://bit.ly/3rzlfvd
PharmaVentures is a specialist healthcare consultancy which delivers practical and cost-effective solutions to clients world-wide in the pharmaceutical, biotechnology, healthcare, finance & related service sectors.. . . . Strategy, Analysis, Evaluation. Expert Reports, Due Diligence, Deal Benchmarking, Structuring & Negotiation, Product Partner Identification
No data available
Founded in the UK in 2002, Pharmidex provides high quality experimental preclinical ADMET/PK data, critical to the progression of drug discovery programmes. We have comprehensive in-house laboratory facilities as well as extensive in-vitro and in-vivo assay options. This enables us to provide tailored studies designed to meet individual project needs. Through extensive knowledge of drug discovery and development, Pharmidex has been able to deliver a high level of customer satisfaction and forge several strategic international alliances, focusing on operations in the following areas: in vitro ADMET, in-vivo Pharmacology, CNS Drug Discovery, Bioanalysis, Metabolite Identification, Bioimaging, and Zebrafish.
PhoreMost™ is focused on bringing more effective and affordable targeted medicines to patients. To achieve this aim, PhoreMost is developing a next-generation phenotypic screening technology that can discern the best new targets for future therapy and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases. Based on the company's proprietary Protein Interference (PROTEINi®) technology, PhoreMost has developed SITESEEKER®; a platform that can systematically unmask cryptic druggable sites in the human genome and then link them to useful therapeutic functions in a live-cell context.
Watch our Member Showcase Video https://bit.ly/3rtFquQ
Pioneer Group is a leading force in life sciences and tech, providing cutting-edge lab and office spaces, investment, and expertise to fuel innovation. We support ambitious start-ups, scale-ups, and established firms with world-class facilities, strategic funding, and tailored business guidance.
Our campuses connect scientists, entrepreneurs, and investors, accelerating breakthroughs in health, sustainability, and technology. By fostering collaboration and long-term partnerships, we create dynamic environments where ideas flourish, businesses scale, and industries evolve. Pioneer Group is committed to shaping the future by bridging science and business, driving economic growth, and delivering meaningful impact.
Our campuses connect scientists, entrepreneurs, and investors, accelerating breakthroughs in health, sustainability, and technology. By fostering collaboration and long-term partnerships, we create dynamic environments where ideas flourish, businesses scale, and industries evolve. Pioneer Group is committed to shaping the future by bridging science and business, driving economic growth, and delivering meaningful impact.
DefiniGEN is a game-changing company headquartered in Cambridge, UK, with a mission to navigate drug development programs through uncertain terrain, minimizing risk while reducing costs and paving the way for a more efficient and effective future in the field of drug discovery. Our technology is revolutionizing liver models for efficacy and toxicology screening, utilizing a platform that enables the large-scale generation of hepatocyte-like cells ( Opti-Heps) with functional relevance comparable to human primary cells. Our Opti-Heps effectively simulate crucial aspects of disease pathophysiology across various liver conditions, providing a more accurate understanding for drug development. By integrating CRISPR/Cas9 technology, DefiniGEN replicates disease phenotypes catering to unmet needs for in vitro efficacy testing and enabling the study of previously inaccessible rare monogenic liver diseases. Our Opti-Heps successfully replicate all aspects of hepatocyte pathophysiology, allowing them to replace primary liver cells in many aspects of toxicity testing. This breakthrough provides scientists with a reliable and consistent supply of highly functional hepatocytes for the first time.